The Extent of Engagement With Telehealth Approaches by Patients With Advanced Cancer: Systematic Review

William Goodman¹, BSc, MSc; Anne-Marie Bagnall², BSc, PhD; Laura Ashley³, BSc, PhD; Desiree Azizoddin⁴,⁵, BA, MA, PsyD; Felix Muehlensiepen⁶, BA, MPH, Dr Rer Med; David Blum⁷, MD, PhD; Michael I Bennett¹, MBChB, MD; Matthew Allsop¹, BSc, PhD

¹Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom
²School of Health, Leeds Beckett University, Leeds, United Kingdom
³Leeds School of Social Sciences, Leeds Beckett University, Leeds, United Kingdom
⁴Department of Emergency Medicine, Brigham and Women's Hospital, Boston, MA, United States
⁵Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, United States
⁶Brandenburg Medical School Theodor Fontane, Neuruppin, Germany
⁷Competence Center Palliative Care, University Hospital Zurich, Zurich, Switzerland

Corresponding Author:
Matthew Allsop, BSc, PhD
Leeds Institute of Health Sciences
University of Leeds
Worsley Building
Clarendon Way, Woodhouse
Leeds, LS2 9LU
United Kingdom
Phone: 44 1133434185
Email: m.j.allsop@leeds.ac.uk

Abstract

Background: Telehealth approaches are increasingly being used to support patients with advanced diseases, including cancer. Evidence suggests that telehealth is acceptable to most patients; however, the extent of and factors influencing patient engagement remain unclear.

Objective: The aim of this review is to characterize the extent of engagement with telehealth interventions in patients with advanced, incurable cancer reported in the international literature.

Methods: This systematic review was registered with PROSPERO (International Prospective Register of Systematic Reviews) and is reported in line with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. A comprehensive search of databases was undertaken for telehealth interventions (communication between a patient with advanced cancer and their health professional via telehealth technologies), including MEDLINE, Embase, CINAHL, PsycINFO, Cochrane Library, Sociological Abstracts, and Web of Science, from the inception of each electronic database up until December 31, 2020. A narrative synthesis was conducted to outline the design, population, and context of the studies. A conceptual framework of digital engagement comprising quantitative behavioral measures (frequency, amount, duration, and depth of use) framed the analysis of engagement with telehealth approaches. Frequency data were transformed to a percentage (actual patient engagement as a proportion of intended engagement), and the interventions were characterized by intensity (high, medium, and low intended engagement) and mode of delivery for standardized comparisons across studies.

Results: Of the 19,676 identified papers, 40 (0.2%) papers covering 39 different studies were eligible for inclusion, dominated by US studies (22/39, 56%), with most being research studies (26/39, 67%). The most commonly reported measure of engagement was frequency (36/39, 92%), with substantial heterogeneity in the way in which it was measured. A standardized percentage of actual patient engagement was derived from 17 studies (17/39, 44%; n=1255), ranging from 51% to 100% with a weighted average of 75.4% (SD 15.8%). A directly proportional relationship was found between intervention intensity and actual patient engagement. Higher engagement occurred when a tablet, computer, or smartphone app was the mode of delivery.

Conclusions: Understanding engagement for people with advanced cancer can guide the development of telehealth approaches from their design to monitoring as part of routine care. With increasing telehealth use, the development of meaningful and context-
and condition-appropriate measures of telehealth engagement is needed to address the current heterogeneity in reporting while improving the understanding of optimal implementation of telehealth for oncology and palliative care.

**Trial Registration:** PROSPERO (International Prospective Register of Systematic Reviews) CRD42018117232; https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018117232

**KEYWORDS**
systematic review; advanced cancer; engagement; digital health; telehealth; mobile phone

**Introduction**

**Background**

Cancer ranks as a leading cause of death worldwide and is a leading cause of premature death in most countries [1]. For people living with advanced cancer, fluctuating unmet needs can be experienced over time with disease progression [2]. Common symptoms include pain, experienced in approximately two-thirds (66.4%) of patients with advanced disease [3], alongside breathlessness, nausea and vomiting, and fatigue [4]. Typically, individuals experience more than one symptom, with an average of 14 symptoms for those with advanced cancer [5]. Such physical symptoms often exist alongside deterioration across physical, psychological, social, spiritual, and overall quality of life (QOL) trajectories [6]. There remain gaps in supporting care delivery for patients with cancer, including barriers in health communication with health care providers, lack of care coordination, and challenges in accessing care [7].

Telehealth and telehealth interventions refer to a method in which the patient and health care professional can communicate clinical information remotely via a number of different mediums such as telephone, web-based methods, and mobile apps [8]. This method is increasingly used to deliver cancer care as it provides opportunities for efficient and flexible service delivery and enables clinicians to maintain involvement independent of the physical location of the patients or clinicians [9-12]. These characteristics have also driven their increased application to support delivery of care during the COVID-19 pandemic, enabling avoidance of direct physical contact while contributing to provision of continuous care in the community. Telephone-based approaches have been highlighted as a possible means of overcoming gaps in service delivery for patients with cancer [7], including reducing the travel required to access support services that can lead to physical, psychological, and financial stress [13,14]. Examination of telehealth approaches for patients with chronic diseases has found varying effects, with improved self-management of diabetes and reduced mortality and hospital admissions in heart failure, but these improvements have not been observed across other conditions, including cancer [8]. Emerging evidence is mixed, with a recent review that focused on all cancer stages demonstrating clinical equipoise, with no discernible difference between telehealth and usual care in improving QOL [15]. However, a recent systematic review focusing specifically on patients with advanced cancer and diverse web and technological interventions (largely providing psychosocial, self-management, and expert-guided support) found that most approaches suggested some degree of efficacy relating to QOL and psychosocial well-being [16]. However, we do not know how well people with advanced cancer engage with these interventions.

With emerging clinical validation demonstrating the potential of digital technology approaches to improve care and outcomes of patients with advanced cancer, usability must also be considered [17]. Subjective aspects of usability require a better understanding, specifically regarding user satisfaction and engagement [17]. Patient engagement can be an important factor in the success of health interventions, leading to better intended health outcomes for the patient and lower health care costs [18]. As such, the effectiveness of telehealth interventions in improving health outcomes is heavily dependent on patient engagement. However, patient engagement is a broad term that can cover multiple levels of how a patient interacts with an intervention. For the purposes of this review, with a focus on technology-based interventions, engagement will be used to refer to the specific quantitative measures of behavior of engagement as defined by Perski et al [19] (i.e., comprising the frequency, amount, duration, depth of use, and other measures of use and interaction with a digital health intervention). A previous systematic review found that information technology platforms (eg, mobile phone devices, internet-based interventions, social media, and other web-based communication tools) can help engage patients in health care processes and motivate health behavior change [20]. However, interventions with the intention to help support patients in managing chronic conditions can be complex. There is a need to understand whether different aspects of telehealth interventions uniquely influence patient engagement, especially for patients with advanced cancer who often experience a high symptom burden and functional impairment [21]. Understanding patients’ engagement with telehealth interventions is necessary to further evaluate and refine the implementation of these emerging and promising approaches for patients with advanced cancer. Therefore, there is a need to understand how patients with advanced cancer engage with telehealth interventions and which aspects of these interventions may influence engagement.

**Objectives**

Past systematic reviews have sought to synthesize the evidence of telehealth interventions among patients with cancer and survivors but have not explored interventions solely intended for and tested on patients with advanced, incurable cancer [15,16]. Understanding patient engagement can help us evaluate and refine further design, development, and evaluation of telehealth approaches for people with advanced cancer. A companion review [22] explored the clinical and cost-effectiveness of the interventions on health and health

https://cancer.jmir.org/2022/1/e33355
system outcomes, whereas this review synthesizes the data on patient engagement with the interventions. The aims of this review are as follows: (1) to characterize the extent of behavioral engagement of people with advanced, incurable cancer with telehealth interventions and (2) to explore factors that influence engagement with telehealth interventions.

**Methods**

**Information Sources**

This systematic review was registered with PROSPERO (International Prospective Register of Systematic Reviews; CRD42018117232). A systematic review of the literature was conducted in the following databases: MEDLINE, Embase, CINAHL, PsycINFO, Cochrane Library, Web of Science, and Sociological Abstracts, with studies included from the inception of each electronic database up until December 31, 2020. No lower cutoff date was chosen as there has not been a previous review looking into engagement with telehealth interventions in this population. An example search strategy used for MEDLINE can be found in Multimedia Appendix 1 and includes keywords and medical subject headings. The development of the search strategy was supported by information specialists at the University of Leeds. This search was supplemented by forward and backward citation searching of key papers. This review was reported in line with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 guidelines. The Centre for Reviews and Dissemination guidelines directed our process for conducting this systematic review and the decisions made [23].

**Eligibility Criteria**

Studies were eligible for inclusion in the review if the following applied:

1. They involved a telehealth intervention, which is defined as “any intervention in which clinical information is transferred remotely between patient and health care provider, regardless of the technology used to record or transmit the information” [8]. This could include symptom measuring or monitoring (eg, Patient-Reported Outcome Measures); education, information giving, and support, including decision aids and advanced care planning; psychological interventions; or medical consultation (telemedicine or teleconsultation). Participants could be located anywhere as long as the intervention that was carried out conformed to the telehealth definition.
2. They included participants of any age who were living with cancer of any type that could not be cured (advanced, metastatic, or terminal). This included people who had been treated with curative intent but whose cancer had recurred or progressed, those not being treated with curative intent, and those at or near end of life.
3. They included a measure of engagement as an outcome or reported as part of the study findings. In this review, we used the measures conceptualized as behavior that were identified by Perski et al [19]: frequency, amount, duration, and depth of use.
4. The studies were carried out in any country at any time.
5. Risk of bias was not used as a selection criterion for inclusion in the review.

Studies were excluded when the following applied:

1. The participants included patients with cancer currently being treated with curative intent, and the studies had mixed populations (ie, not 100% of the sample were people with cancer that could not be cured), unless findings pertaining to our population of interest were presented separately in the results section.
2. The studies did not report primary data (eg, systematic reviews, study protocols, conference abstracts, editorials, and commentaries).
3. The studies were not in the English language.

**Study Selection and Data Collection Process**

In total, 2 authors (WG and MA) reviewed titles, abstracts, and full-text papers, assessing them for eligibility independently. Any disagreements were resolved through discussion.

Data from the included studies were extracted into a predesigned form by WG and verified by MA to capture study characteristics (design, sample size, cancer type, gender, age, and outcomes). Data were also extracted based upon the items included in the Template for Intervention Description and Replication checklist (why, what, who provided, how, where, when and how much, tailoring, modifications, and how well) [24].

**Quality Assessment**

The included studies were assessed for methodological quality and risk of bias independently by 2 authors (WG and MA), with any disagreements resolved through discussion. The risk of bias for randomized controlled trials (RCTs) and nonrandomized studies was assessed using the Mixed Methods Appraisal Tool [25].

**Data Synthesis**

A narrative synthesis [26] was conducted to outline the design, population, and context (mode of delivery, health care provider, and intervention intensity) of the individual studies. Studies were categorized by their approach to examining intervention effect, differentiating between those exploring pure intervention effect (eg, using blinded RCT designs) and those exploring effect in the context of routine health care [27]. For the primary outcome of engagement, a deductive and inductive approach was taken using the definitions of engagement behavior outlined by Perski et al [19] while also ensuring that other engagement-related data were captured. Engagement data were identified and split into categories based upon the type of engagement the studies measured: frequency (how often contact was made with the intervention over a specified period), the amount or breadth (the total length of each intervention contact), duration (the period over which participants were exposed to an intervention), and depth (variety of content used) [19]. Across these 4 measures, studies were grouped together based upon how they measured the outcome, which was then summarized. Data from the included studies relating to frequency of use by patients, where reported, were transformed to a percentage of actual patient engagement compared with intended engagement.
with the intervention to provide a standardized statistical comparison. When overall engagement percentages were calculated, these were weighted by sample size.

To draw associations between the calculated percentage of actual patient engagement, the intensity of the intervention (for the patient and health professional), and mode of delivery, we had to simplify these characteristics. The intensity of the interventions for both the patient and the health professional was coded by a member of the research team (WG). WG reviewed the intervention description in each included study to determine the expected engagement with the intervention for patients and health professionals. This referred to any interaction (both scheduled and unscheduled) that was anticipated or planned with the intervention (eg, a patient having a telephone consultation with a health professional or submitting data via a web-based system). For articles where a second opinion was requested by WG, a second reviewer (MA) discussed the study with WG until a consensus was achieved on the expected engagement reported. The expected engagement was simplified into categories of high, medium, and low expected engagement to make comparisons across studies. For patients, low expected engagement referred to only having ≤3 contacts with the intervention, a medium level of engagement was 4 to 7 expected contacts, and a high level of engagement was ≥8 expected contacts or more than daily reporting of symptoms. A previous study of engagement with a web-based mindfulness intervention identified similar levels of high and low participant engagement (low: 0-4 and high: 5-7); however, a third category was added for this review to account for the studies with >7 contacts [28]. For health professionals, the categories mirrored those for patients if the health professional was required to make contact with the patient (eg, low was ≤3 contacts, medium was 4 to 7 contacts, and high was ≥8 contacts). If the health professional was required to only make contact with the patient when prompted to do so by a patient’s entry on a system or survey, it was coded as low contact on the part of the health professional. For each intervention, we also coded the mode of delivery (eg, telephone, smartphone, or web-based), including interventions where multiple modes were used. We were then able to look at associations between the mode of delivery, expected level of engagement (high, medium, or low for the patient and health professional), and the percentage of actual patient engagement with the intervention.

Results

Search Results

Of the 19,676 papers that were identified in the database search, 0.2% (40/19,676) of papers covering 39 different studies were eligible for inclusion in the systematic review [29-68]. Figure 1 outlines the PRISMA flow diagram for the included studies and the reasons for exclusion of studies.

Study Characteristics

Table 1 includes a summary of the characteristics of the included studies. Table 2 outlines the characteristics of the included interventions and the engagement outcomes. The included studies had a sample size ranging from 6 [61] to 766 [31] and included multiple RCTs (16/39, 41%) [30,31,33-35,37-39,43-45,48,50,57,63,67,68], with most studies being conducted in the United States (22/39, 56%) [29-31,33,34,37-41,43,45,46,48,50,54,57,59,60,66-68]. Of the 39 studies included in the review, 13 (33%) explored intervention effects in the context of routine care implementation [29,32,36,41,42,49,51,52,58,60-62,64], with the remainder exploring intervention effects often using a blinded controlled trial design.
Table 1. Characteristics of the included studies (N=39).

| Study             | Country          | Study design  | Sample size | Type of cancer                                                   | Age (years)          | Female participants, n (%) |
|-------------------|------------------|---------------|-------------|-----------------------------------------------------------------|----------------------|---------------------------|
| Alter et al [29]  | United States    | Pilot         | 8           | Colorectal                                                      | Range 59-79          | 5 (63)                    |
| Badr et al [30]   | United States    | RCT<sup>a</sup> | 39          | Lung                                                           | Mean 68 (SD 10)      | 29 (74)                   |
| Basch et al [31]  | United States    | RCT           | IG: 444; CG: 325 | Breast, genitourinary, gyneco-logic, or lung                  | IG: median 61; CG: median 62 | IG: 257 (58); CG: 187 (58) |
| Bensink et al [32]| Australia        | Feasibility   | 11          | Advanced cancer, type NR                                      | Range 3-18           | NR                        |
| Bouchard et al [33]| United States    | RCT           | 192         | Prostate                                                       | Mean 69 (SD 9)       | 0 (0)                     |
| Bruera et al [34]| United States    | RCT           | 190         | Advanced cancer, type NR                                      | Median 58 (range 25-84) | 128 (67)                 |
| Chambers et al [35]| Australia       | RCT           | 189         | Prostate                                                       | Mean 70 (SD 9)       | 0 (0)                     |
| Chavarri-Guerra et al [36]| Mexico | Observational study | 45 | Advanced cancer, type NR                                      | Median 68 (range 33-90) | 26 (58)                 |
| Cheung et al [37]| United States    | RCT           | 39          | Breast                                                         | NR                   | 39 (100)                 |
| Cheville et al [38,39]| United States | RCT           | 516         | Multiple myeloma, myelodys-plastic syndrome, or lymphoma       | Mean 66 (SD 11)      | 257 (50)                 |
| Chow et al [40]   | United States    | Feasibility   | 190         | Advanced cancer, type NR                                      | Median 68 (range 39-89) | 94 (49)                 |
| Cluver et al [41]| United States    | Feasibility   | 10          | Advanced cancer, type NR                                      | Mean 50 (range 26-61) | 7 (70)                    |
| Dixon et al [42]  | Canada           | Feasibility   | 69          | Advanced cancer, type NR                                      | Mean 69              | 19 (28)                   |
| Donovan et al [43]| United States    | RCT           | 65          | Ovarian                                                        | Mean 57 (SD 9)       | 65 (100)                 |
| Eldeib et al [44]| Egypt            | RCT           | IG: 44; CG: 38 | Colorectal or gastric adenocarcinoma               | IG: mean 50 (SD 11); CG: mean 45 (SD 13) | IG: 28 (64); CG: 24 (63) |
| Flannery et al [45]| United States   | RCT           | IG: 30; CG: 15 | Lung                                                            | IG: mean 66 (SD 8); CG: mean 61 (SD 9) | IG: 7 (41); CG: 5 (45) |
| Fleisher et al [46]| United States   | Feasibility   | 22          | Advanced cancer, type NR                                      | Range 37-77          | 11 (50)                   |
| Fox et al [48]    | United States    | RCT           | 192         | Prostate                                                       | Mean 71 (SD 8); CG: mean 71 (SD 9) | 0 (0)                     |
| Fox et al [47]    | Australia        | Feasibility   | 15          | Melanoma                                                       | 26-49 years: n=4 (27%); 50-64 years: n=6 (40%); ≥65 years: n=5 (33%) | 7 (47)                  |
| Friis et al [49]  | Denmark          | Feasibility   | 20          | Lung                                                           | Median 70.5 (range 54-86) | 7 (35)                   |
| Gustafson et al [50]| United States  | RCT           | IG: 144; CG: 141 | Lung                                                            | IG: mean 62 (SD 11); CG: mean 61 (SD 10) | IG: 62 (50); CG: 59 (48) |
| Haddad et al [51]| Canada           | Feasibility   | IG: 102; CG: 118 | Lung and others                                                  | IG: mean 62 (range 35-83); CG: mean 60 (range 31-87) | IG: 28 (50); CG: 25 (45) |
| Henneemann-Krauss et al [52]| Brazil | Observational study | 12 | Advanced cancer, type NR                                      | Mean 68 (SD 9)       | 5 (42)                    |
| Keikes et al [53] | Netherlands      | Feasibility   | 155         | Colorectal                                                      | NR                   | NR                        |
| Study | Country        | Study design | Sample size | Type of cancer                                                                 | Age (years)                                                                 | Female participants, n (%) |
|-------|----------------|--------------|-------------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------|
| Liu et al [54] | United States | Pilot        | 16          | Ovarian                                                                        | Median 58 (range 36-80)                                                    | NR                          |
| Nemecek et al [55] | Austria       | Feasibility  | 15          | Non–small cell lung cancer, melanoma, and pancreatic cancer                    | Mean 50                                                                     | NR                          |
| Rasschaert [56]   | Belgium        | Feasibility  | 11          | Colorectal, gastric or esophageal, pancreatic, and cholangiocarcinoma          | Median 57 (range 44-74)                                                    | 6 (55)                      |
| Rose et al [57]   | United States  | RCT          | 210         | Advanced cancer, type NR                                                      | 40-60 (n=109); 61-80 (n=101)                                              | 69 (33)                     |
| Sardell et al [58]| United Kingdom | Feasibility  | 45          | Glioma                                                                         | Median 50 (range 23-69)                                                    | 15 (33)                     |
| Schmitz et al [59]| United States  | Pilot        | 7           | Breast                                                                         | Mean 61                                                                     | 7 (100)                     |
| Sherry et al [60] | United States  | Pilot        | 41          | Lung                                                                           | Mean 66 (SD 10)                                                            | 29 (71)                     |
| Trojan et al [61]| Switzerland    | Observational study | 6   | Prostate, lung, and urothelial cancer                                           | NR                                                                         | 0 (0)                       |
| Upton [62]        | United Kingdom | Pilot        | 18          | Melanoma                                                                       | NR                                                                         | NR                          |
| Voruganti et al [63]| Canada       | RCT          | IG: 24; CG: 24 | Breast, colorectal, lung, prostate, ovarian, head and neck, and leukemia, myeloma, or lymphoma | IG: mean 60 (SD 15); CG: mean 60 (SD 14)                                   | IG: 13 (62); CG: 16 (76)    |
| Watanabe et al [64]| Canada       | Pilot        | 44          | Breast, lung, and leukemia, myeloma, or lymphoma                              | Median 60 (range 20-88)                                                    | 18 (41)                     |
| Weaver et al [65]| United Kingdom | Pilot        | 26          | Breast, colorectal                                                             | Mean 57                                                                     | 12 (46)                     |
| Wright et al [66] | United States  | Pilot        | 10          | Gynecologic                                                                    | Mean 60 (SD 11)                                                            | 10 (100)                    |
| Yanez et al [67]  | United States  | RCT          | 74          | Prostate                                                                       | Mean 69 (SD 9)                                                             | 0 (0)                       |
| Yount et al [68]  | United States  | RCT          | IG: 123; CG: 130 | Lung                                                                            | IG: mean 61 (SD 10); CG: mean 60 (SD 10)                                  | IG: 66 (54); CG: 62 (48)    |

aRCT: randomized controlled trial.
bIG: intervention group.
cCG: control group.
dNR: not reported.
| Study            | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider) | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|------------------|----------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| Alter et al [29] | Four 30-minute telephone sessions (2 months)            | Content: nurse gathered information on medical and psychological history and discussed effects of cancer on their lives and relationships. Concerns were identified and discussed, strengths in dealing with problems were also identified, and patients were encouraged to use strategies and resources that had been highlighted. | Frequency: all 4 patients completed all 4 telephone sessions. Actual patient engagement: 100%. |
| Badr et al [30]  | Six 60-minute telephone sessions (6 weeks)              | Content: a manual was used covering six areas: self-care, stress and coping, symptom management, effective communication, problem solving, and maintaining and enhancing relationships. Telephone sessions reviewed the content of the manual with patients and carers and set homework for following week. | Frequency: 90% of patient–caregiver dyad phone calls were made on time. One member had scheduling conflicts, but all were made up with another call. Actual patient engagement: 100%. |
| Basch et al [31] | Participants remained in the study until treatment had concluded or they had died. All intervention participants reported symptoms on tablet or computer kiosks at clinic, but computer-literate participants also sent weekly emails to complete surveys at home (not set). | Content: participants who were computer-experienced completed symptom-tracking surveys in between clinic visits; if symptoms worsened, this would trigger an email alert to nurses, and participants were encouraged to call if concerned. Those who were computer-inexperienced completed surveys at the clinic before meeting with their clinician. Reports were provided to clinicians but no guidance on what action to take. | Frequency: 73% of intervention participants completed a symptom self-report at any clinic visit, but this did not lead to a difference in the number of nurse calls received compared with the control group (12.8 vs 12.9). |
| Bensink et al [32] | Individually tailored. No set engagement (not set). | Content: the families were provided with videoconference technology, which was used to provide patient assessment and monitoring, family education, communication, and counseling by nurses and other support by social workers or other medical staff. | Frequency: 7 of 11 families received telephone calls, with a total of 25 made and an average of 2.3. Amount: calls lasted for a median length of 20 (IQR 15-33) minutes. |
| Bouchard et al [33] | Ten 90-minute group sessions (10 weeks) | Content: involved group teleconferences teaching stress and self-management skills for men with prostate cancer with disease-relevant examples. | Frequency: an average of 7.5 (SD 3.1) sessions were attended for the intervention group. Actual patient engagement: 75%. |
| Study              | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider) | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|--------------------|--------------------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Bruera et al [34]  | 4-6 calls (2 weeks)                                     | Content: the calls involved symptom assessment, a review of the types and dosages of medications and their effects, and psychosocial support and patient education. The patient could ask questions, and the nurse asked about their well-being. | Frequency: no significant difference in the number of phone calls received across any of the four groups: drug and intervention phone call (median 4, IQR 3-5), drug and control call (median 5, IQR 4-6), placebo and intervention phone call (median 5, IQR 4-6), and placebo and control call (median 4, IQR 4-5). |
| Chambers et al [35] | Eight 75-minute group sessions (8 weeks)               | Content: an introductory call was used to prepare participants for the group call, and a workbook was used to also guide these group calls. The group calls encouraged peer interaction to support learning mindfulness skills and tackling challenges. Participants were encouraged to engage in 1 mindfulness meditation daily. | Frequency: 28% (n=26) attended 0 sessions, 20% (n=19) attended 1 to 3 sessions, 22% (n=21) attended 4 to 7 sessions, and 30% (n=28) attended 8 sessions. Amount: the average length of a session was 85 (SD 12) minutes. |
| Chavarri-Guerra et al [36] | Individually tailored. No set engagement (not set). | Content: care needs assessments were administered remotely; the multidisciplinary team met to discuss intervention plans, which were then put to the patient. If acceptable, these were then conducted remotely. | Frequency: 163 supportive care interventions were provided to 45 patients (median number of interventions per patient 3, range 1-13). Amount: 0-15 minutes: 38 (23.3%), 16-30 minutes: 58 (35.6%), 31-45 minutes: 37 (22.7%), >45 minutes: 29 (17.8%), (SMS text messaging): 1 (0.6%). Depth: psychological care: 54 (33.1%), pain and symptom control: 41 (25.1%), nutritional counseling: 20 (12.6%), physical therapy: 14 (8.5%), end-of-life care: 13 (7.9%), geriatric assessment: 8 (4.9%), advance directive completion: 8 (4.9%), psychiatric care: 5 (3%). |
| Cheung et al [37]  | Five 1-hour sessions (5 weeks)                          | Content: each session taught participants 3 out of 8 skills (noticing positive events, capitalizing on or savoring positive events, gratitude, mindfulness, positive reappraisal, focusing on personal strengths, setting and working toward attainable goals, and small acts of kindness), and they were instructed to practice every day. | Frequency: all 12 participants completed 1 session, 11 participants completed 2 sessions, and 10 participants completed all 5 sessions. |
| Cheville et al [38,39] | 8 telephone sessions with fitness care manager, 8 sessions with PT (more if PT thought needed), and pain management intervention arm received call from pain care manager; who then monitored patient-reported pain levels over the course of the study (4 weeks) | Content: each session taught participants 3 out of 8 skills (noticing positive events, capitalizing on or savoring positive events, gratitude, mindfulness, positive reappraisal, focusing on personal strengths, setting and working toward attainable goals, and small acts of kindness), and they were instructed to practice every day. | Frequency: all 12 participants completed 1 session, 11 participants completed 2 sessions, and 10 participants completed all 5 sessions. |
| Study             | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider)                                                                 | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|------------------|-------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Chow et al [40]  | 5 telephone sessions (12 weeks)                      | • Content: patients completed surveys on symptom distress, any questions were referred to palliative nurses, and clinic visits were only scheduled when necessary.  
  • Mode of delivery: telephone. Individual basis.  
  • Health care provider: health care professional trainee. | • Frequency: of the 190 patients, 62% completed the week 1 and 2 phone call, 57% completed the week 4 phone call, 44% completed the week 8 phone call, and 40% completed the week 12 phone call.  
  • Actual patient engagement: 53%. |
| Cluver et al [41] | Six 60-minute sessions (not reported)                | • Content: sessions involved cognitive therapy.  
  • Mode of delivery: telephone and in person. Individual basis.  
  • Health care provider: therapist. | • Frequency: of the 53 completed sessions, 21 were conducted via videophone, and 32 were conducted face-to-face. One session was missed. |
| Dixon et al [42] | 2 telephone sessions (4 weeks)                        | • Content: follow-up calls following radiation therapy were used to monitor patients' symptoms.  
  • Mode of delivery: telephone. Individual basis.  
  • Health care provider: radiation therapist. | • Frequency: 72% (38/53) of patients completed the telephone assessment at the 1- or 4-week intervals.  
  • Actual patient engagement: 72%. |
| Donovan et al [43] | Based upon participants’ engagement (3 weeks)       | • Content: patients had 3 target symptoms that they worked with the nurse to manage through the message board. The intervention encouraged the patient to understand their problem, discuss their concerns, and understand that they could make positive changes to manage their symptoms. Gaps in knowledge were addressed, and the benefits of new strategies were discussed as well as the setting of goals to achieve these. The patient was then followed up to see whether this worked or whether modifications needed to be made.  
  • Mode of delivery: web-based. Individual basis.  
  • Health care provider: nurse. | • Frequency: the mean number of postings for the 33 women randomized into WRITE Symptoms was 15.87 (median 14, range 0-41).  
  • Amount: the mean length of participant posts was 260.50 (median 210, range 0-808) words.  
  • Duration: for those completing the intervention, it took the nurse–participant dyads an average of 79 (median 76, range 37-185) days to complete all elements of the intervention.  
  • Depth: 25 (75.8%) participants assigned to WRITE Symptoms completed all elements of the intervention. |
| Eldeib et al [44] | Weekly calls (dependent on length of treatment)     | • Content: intervention group 1: tele-delivery of rehabilitation services. Education on role of physical activity in symptom management, consequences of cancer and cancer treatment on loss of muscle bulk and power, and adverse symptoms during exercise. REST to improve functional status. FSP to increase activity levels and aerobic conditioning. Treatment of physical impairments (if any detected) through PT treatment plans. Intervention group 2: same as group 1 with additional pain management to monitor and adjust dosages and medication as needed.  
  • Mode of delivery: telephone and in person. Individual basis.  
  • Health care provider: primary care team, a PT acting as a fitness care manager, a physical medicine and rehabilitation physician, and a local physical therapist. | • Frequency: no difference in remote monitoring contacts across the three groups: mean 10.3 (SD 4.4), mean 10.7 (SD 5.2), and mean 10.2 (SD 4.5). Contacts with the fitness care manager were similar across IG 1 and 2 (mean 7.6, SD 2.9, range 1-21 vs mean 7.2, SD 3.1, range 1-22). The proportion of surveys completed via the web as opposed to the IVR surveys was similar for each arm: CG: 1648 (66%), IG 1: 1721 (74%), and IG 2: 1632 (69%). |
|                 |                                                       | • Frequency: of the 190 patients, 62% completed the week 1 and 2 phone call, 57% completed the week 4 phone call, 44% completed the week 8 phone call, and 40% completed the week 12 phone call.  
  • Actual patient engagement: 53%. | • Amount: time spent with the fitness care manager was also similar across IG 1 and 2: mean 16.2 (SD 15.2, range 1-124) minutes for IG 1 and mean 16.6 (SD 15.4, range 1-87) minutes for IG 2.  
  • Actual patient engagement: IG 1: 95%; IG 2: 90%. |
| Study                      | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider)                                                                 | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|----------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Flannery et al [45]       | 8 telephone sessions (8 weeks)                       | • Content: phone calls were used to assess any adverse effects and recommend suitable strategies to remedy this. Adherence to medication was also reinforced.  
  • Mode of delivery: telephone. Individual basis.  
  • Health care provider: pharmacist. | • Frequency: of the 57% (17/30) of participants retained in the intervention arm, the mean number of intervention calls received was 5.50 (SD 2.48); 8 of 17 participants received all 8 interventions.  
  • Actual patient engagement: 68.8%. |
| Fleisher et al [46]       | Dependent on participant engagement with web-based survey and skills module (not reported) | • Content: a web-based survey on patient goals, values, and communication preferences, followed by a training module on communication skills. A report was generated for the physician to help guide their next session.  
  • Mode of delivery: web-based. Individual basis.  
  • Health care provider: oncologist. | • Frequency: 18 began the communication aid, and 15 completed it.  
  • Amount: the average time for completing the entire program was 65 minutes—52 minutes spent on the survey and 13 spent on the module.  
  • Actual patient engagement: 83.3%. |
| Fox et al [48]            | Ten 90-minute sessions (10 weeks)                   | • Content: facilitator-led relaxation exercises (eg, deep breathing, progressive muscle relaxation, mindfulness meditation, and guided imagery). Psychoeducational sessions focused on stress management. Participants also given homework to practice skills learned in weekly sessions.  
  • Mode of delivery: web-based. Group delivery.  
  • Health care provider: therapist. | • Frequency: week 1: 74% (n=70) attended IG meeting, and 75% (n=73) attended CG meeting. Week 10: 73% (n=69) attended IG meeting, and 82% (n=80) attended the CG meeting. |
| Fox [47]                  | 1 telephone call (not set)                           | • Content: the outreach call was tailored to the needs of the participant and considered their internal and external environments, including mental, physical, spiritual, psychological, cognitive, relational, social, and cultural aspects.  
  • Mode of delivery: telephone. Individual basis.  
  • Health care provider: social worker or counselor and nurse. | • Amount: mean duration of calls was 56.5 (SD 15.72) minutes. Approximately 71% of calls lasted ≤1 hour. |
| Friis et al [49]          | Once a week for 4-week web-based symptom reporting, telephone call if threshold exceeded (4 weeks) | • Content: patients filled in health questionnaires in real time, which could be accessed by their health team. Those who needed clinical attention had alerts sent to the clinical team.  
  • Mode of delivery: telephone. Individual basis.  
  • Health care provider: social worker or counselor and nurse. | • Frequency: 55% (37/67) of questionnaires answered exceeded the threshold and led to further action by a clinical nurse. Approximately 30% (20/67) of the questionnaires resulted in a phone call. |
| Gustafson et al [50]      | Dependent on participant engagement (25 months long or 13 months after patient death for caregiver) | • Content: nurses phoned participants weekly and assessed their symptoms on 16 common symptoms experienced by those with lung cancer. Any reported symptom required asking questions about the somatic aspects of the symptom.  
  • Mode of delivery: telephone. Individual basis.  
  • Health care provider: nurse. | |
| Study | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider) | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|-------|-------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|       |                                                       | • Content: access to Coping with Lung Cancer website, which provided information on lung cancer, care giving, and bereavement. It also acted as a communication channel between peers, experts, and clinicians. Feedback was also provided by algorithms based on collected data. Tools to help organize support were also provided. Clinicians received reports before next clinic appointments as well as email alerts when high symptom ratings were reported. | • Frequency: CHESS\(^5\) was used at least once by 73.4% of caregivers and 50% of patients, and 51.6% of caregivers and 34.7% of patients used CHESS ≥ 5 times. |
|       |                                                       | • Mode of delivery: web-based. Patient–caregiver dyad. | • Amount: the median number of minutes of CHESS use was 103 for caregivers and 146 for patients. |
|       |                                                       | • Health care provider: oncologist and enrollment coordinator. | • Depth: the median number of pages viewed was 147 for caregivers and 243 for patients. |
| Haddad et al [51] | 2 telephone sessions (4 weeks) | Content: participants were asked about their symptoms, side effects, and drug dosage. | Frequency: successful contact at week 1 and 4 was achieved for 22 participants of group A, 14 participants only contacted at week 1, and 3 participants only contacted at week 4. A total of 17 participants were not contacted. |
|       |                                                       | • Mode of delivery: telephone. Individual basis. | Actual patient engagement: 54.5%. |
|       |                                                       | • Health care provider: nurse and radiation therapist. | Frequency: in-person consultations: mean 7.42 (SD 6.29), web conferences: mean 6.42 (SD 7.64), and total contacts: mean 25.4 (SD 16.3). |
|       |                                                       |                         | Duration: the mean monitoring time was 195 (SD 175.1) days. |
| Henne mann-Krause et al [52] | Web conferences weekly and face-to-face meetings monthly (continued until patient death) | Content: symptoms were assessed on a scale, and complaints from patients were listened to. In videoconferences, discrepancy between what the patients reported and what the physician could see on-screen were evaluated. | Frequency: 301 patients received a consultation sheet, of whom 155 patients participated in the web-based part of the decision tool (51%). |
|       |                                                       | • Mode of delivery: teleconference, email, telephone, and in person. Individual basis. | Amount: the median overall time spent on web-based decision support was 38 (IQR 18-56) minutes. Time spent was highest on reading treatment background information (median 4, IQR 1-11 minutes) and answering questions about patients' perspective (median 5, IQR 2-11 minutes). |
|       |                                                       | • Health care provider: physicians, nurse, social worker, psychologist, and music therapist. | Actual patient engagement: 51%. |
| Keikes et al [53] | 2 face-to-face consultations and web-based access to decision support tool in between meetings (not reported) | Content: treatment options were discussed with oncologist, and the patient reviewed information available on the web and completed questions on treatment goals. | Frequency: 301 patients received a consultation sheet, of whom 155 patients participated in the web-based part of the decision tool (51%). |
|       |                                                       | • Mode of delivery: web-based. Individual basis. | Amount: the median overall time spent on web-based decision support was 38 (IQR 18-56) minutes. Time spent was highest on reading treatment background information (median 4, IQR 1-11 minutes) and answering questions about patients' perspective (median 5, IQR 2-11 minutes). |
|       |                                                       | • Health care provider: oncologist and a helpdesk. | Actual patient engagement: 51%. |
| Liu et al [54] | Twice daily reporting of blood pressure and diarrhea data reported as needed. Algorithmic feedback and prompts to call HCP\(^i\) when appropriate (4 weeks). | Content: participants reported blood pressure and diarrhea entries, which triggered algorithmic feedback, and the clinical team reviewed this. Email alerts were sent to the clinical team for high results or when a blood pressure check was missed. | Frequency: patients using eCO\(^j\) recorded 98.2% of expected home blood pressure values. All 12 patients were prompted to call at least once, with most being prompted 7 to 20 times. One patient was prompted 54 times but was considered noncompliant. |
|       |                                                       | • Mode of delivery: mobile app. Individual basis. | Actual patient engagement: 98.2%. |
|       |                                                       | • Health care provider: patients’ clinical team. | |
| Study                  | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider) | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|-----------------------|--------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Nemecek et al [55]    | Participant-dependent reporting and contact with physician (until participant death) | • Content: VSee was used to connect patients and their physicians when the patient required medical advice. This was available around the clock. Patients could also input vital signs (temperature, blood pressure, pulse, and oxygen saturation) as well as treatment and other variables (pain, nutrition, and body weight). This could then be reviewed by the physician in charge.  
• Mode of delivery: teleconference. Individual basis.  
• Health care provider: physician.  
• Frequency: a total of 37 telemedical requests were submitted, of which 35 were successful, whereas 2 failed. A total of 638 data entries were performed. Entry count varied between 1 and 265 per patient. |  |
| Rasschaert [56]       | Reported daily treatment intake, toxicity, and disease-related symptoms. Calls made when toxicity levels were high (no set duration; patients used for duration of oral anticancer agent). | • Content: participants were asked to self-report disease-related symptoms and treatment toxicity via an app. This could be accessed by physicians and cancer care providers at clinic visits or when admitted to hospital. Alerts would be sent to caregivers or phone calls would be organized when high toxicities were reported, and the participants were also told to seek help.  
• Mode of delivery: smartphone. Individual basis.  
• Health care provider: data manager, physician, and other health care professionals.  
• Frequency: average daily compliance with registration of treatment intake was 91.2%.  
• Duration: 5 patients used the coach >4 weeks (and only 1 used it for >12 weeks).  
• Actual patient engagement: 91.2%. |  |
| Rose et al [57]       | 1 face-to-face meeting, 1 follow-up call. Patients could then contact the nurse 24 hours a day, 7 days a week at their convenience (2 months). | • Content: the initial meeting occurred in the patient’s home and was to set goals for patient communications and shared decision-making. Coping and communication issues, strategies to address problems, and concerns and expectations were also discussed. Follow-up calls covered the multifaceted impact of cancer and treatment, preparing patients for future therapy or progression, identifying goals either personal or of treatment, identifying further needs of support, supporting positive emotions of oneself, encouraging independence and coping, optimizing social support, addressing practical problems, and referring patients for additional support.  
• Mode of delivery: telephone, email, or in person. Individual basis.  
• Health care provider: nurse.  
• Frequency: average number of monthly contacts was higher among middle-aged group (mean 2.6, SD 2.7) than among the older age group (mean 2.0, SD 1.2).  
• Amount: average length of calls was 10-11 minutes.  
• Duration: average of 62 days of access to intervention. |  |
| Sardell et al [58]    | 3 monthly telephone calls and 1 face-to-face clinic visit at the fourth month. Telephone calls continued if no recurrent or progressive disease (4 months but also participant-dependent). | • Content: the telephone calls followed a semistructured script, which allowed patients to talk freely about their symptoms, how they were feeling, and any problems they had. More structured questions on their neurological status, medication, use of hospital services, return to work, and social activities followed.  
• Mode of delivery: telephone. Individual basis.  
• Health care provider: nurse.  
• Frequency: a total of 254 telephone calls were made, with a median of 4 calls per patient (range 1-14).  
• Amount: median time on calls was 10 (range 2-10) minutes.  
• Duration: median time was 6 (range 2-21) months. |  |
| Schmitz et al [59]    | 3 face-to-face clinic visits in the first year. Telephone calls continued if no recurrent or progressive disease (4 months but also participant-dependent). | • Frequency: average use of the tablet was 69.9 days for 7 participants. |  |
| Study                  | Intervention intensity (duration of the intervention)                                      | Intervention description (content, mode of delivery, health care provider)                                                                 | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement)                                                                 |
|-----------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| Sherry et al [60]     | • Daily app notifications to engage and 1 weekly phone call with navigator (12 weeks)     | • Content: participants received a daily prompt to interact with the app. The app asked a symptom question, which, when answered, prompted different facial expressions from the nurse avatar and different verbal responses. Navigator calls focused on reviewing symptoms and steps, which were compiled in a report and emailed to the clinical care team. | • Frequency: all patients reported that they had read the education pamphlet and received the coaching call.                                                                 |
| Trojan et al [61]     | • Pamphlet and 1 telephone session (1-3 days)                                               | • Content: a personalized pamphlet was presented to the patient based upon problems they noted when completing a distress survey. This was followed up by a phone call a couple of days later to answer any questions and to check understanding. The coach offered referrals to social work, palliative and supportive care services, physical therapy, integrative medicine, financial services, and nutrition. |                                                                                                                                                       |
|                       |                                                                                           | • Mode of delivery: mobile app and telephone. Individual basis.                                                                        |                                                                                                                                                       |
|                       |                                                                                           | • Health care provider: patient navigators.                                                                                                                                                       |
|                       |                                                                                           |                                                                                                                                         |                                                                                                                                                       |
| Upton [62]            | • Participant-dependent reporting of symptoms and side effects (3 months)                  | • Content: patients reported the number, characteristics, and intensity of symptoms and therapy side effects. The symptom severity could trigger alerts to the on-call oncologist, which could result in a telephone consultation. | • Frequency: 1279 symptom entries were recorded. Number of symptom data entries from the 6 patients ranged from 31 to 458 within the 3-month period. A total of 4 of the 6 patients also triggered 14 alerts, all of which correlated to cough, respiratory stress, fever, and fatigue and made patients aware of making contact with their treating center. A total of 6 alerts resulted in telephone consultations with the treating center or oncologist on call. |
|                       |                                                                                           | • Mode of delivery: mobile app and telephone. Individual basis.                                                                        |                                                                                                                                                       |
|                       |                                                                                           | • Health care provider: oncologist.                                                                                                                                                              |
|                       |                                                                                           |                                                                                                                                         |                                                                                                                                                       |
| Voruganti et al [63]  | • 1 telephone assessment (1 day)                                                            | • Content: before ipilimumab infusion, the patient’s blood was tested, and immune-related adverse events were assessed by the nurse. After the infusion, patients were contacted weekly to monitor for immune-related adverse events and for the nurse to provide advice. Patients were also asked to call a 24-hour triage service if experiencing any problems. | • Frequency: over a 1-year period, a total of 56 telephone assessments were undertaken.                                                                 |
|                       |                                                                                           | • Mode of delivery: telephone and in person. Individual basis.                                                                        |                                                                                                                                                       |
|                       |                                                                                           | • Health care provider: nurse.                                                                                                                                                                  |
|                       |                                                                                           |                                                                                                                                         |                                                                                                                                                       |

Sherry et al [60]  
Pamphlet and 1 telephone session (1-3 days)  
Participant-dependent reporting of symptoms and side effects (3 months)  
1 telephone assessment (1 day)  
Dependent on participant engagement with web-based messaging and communication with HCPs (not reported)
| Study | Intervention intensity (duration of the intervention) | Intervention description (content, mode of delivery, health care provider) | Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement) |
|-------|--------------------------------------------------------|---------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Watanabe et al [64] | One 90-minute videoconference with a 30-minute follow-up if necessary (1 day) | Content: the web-based communication tool (Loop) facilitated conversations between patients, caregivers, and health care providers. There was no set communication the tool should be used for, only that it should not be used for urgent communication. Mode of delivery: web-based. Individual basis. Health care provider: oncologist, palliative care physician, and other health care professionals. | Frequency: a total of 72 clinic visits took place, consisting of 44 initial consultations and 28 follow-up visits. Depth: variety of members of MDT seen at consultations: dieticians (56.8%), psychologists (27.3%), respiratory therapists (15.9%), social workers (13.6%), occupational therapists (9.1%), physical therapists (9.1%), and speech language pathologists (4.5%). Actual patient engagement: 100%. |
| Weaver et al [65] | Phone app used twice daily to report symptoms; alerts to nurse generated if toxicity was high or the patient had not self-reported for a while (while on treatment) | Content: patients arranged to attend a local clinic, where a videoconference could be set up with the cancer institute. Blood tests, radiological investigations, and patients’ symptoms and needs were assessed before this, and the results were shared with the team. A total of 3 team members, including the physician, could be on the videoconference, with every member given 15 minutes to interview the patient. After the assessments, the team formed a management plan in discussion with the patient and family, which was sent to the patient’s GP. Mode of delivery: teleconference. Individual basis. Health care provider: nurses, dieticians, psychologists, respiratory therapists, social workers, occupational therapists, physical therapists, speech language pathologists, radiation oncologists, and pharmacists. | Frequency: the patients completed the diary on 92.6% of occasions (range 73.7%-100%). On 396 occasions, self-care advice messages were sent to the patients. Actual patient engagement: 92.6%. |
| Wright et al [66] | Daily app notifications for 30 days. If high-risk symptoms were reported, the patient was told to contact the clinician (30 days). | Content: patients asked to fill out a short diary containing entries for temperature, diarrhea and assessments for vomiting, nausea, mucositis, hand–foot syndrome, and—for patients receiving oxaliplatin—peripheral neuropathy. Alerts were triggered based upon toxic side effects or a lack of reporting, with a nurse available to provide clinical advice. Mode of delivery: mobile app. Individual basis. Health care provider: nurse. | Frequency: study participants were 70% adherent to smartphone surveys. A total of 7 participants answered daily surveys ≥24 times a week. Actual patient engagement: 70%. |
| Yanez et al [67] | Ten 90-minute group sessions (10 weeks) | Content: participants completed daily surveys on quality of life, physical function, and symptoms, of which they ranked the severity. High-risk symptoms initiated a prompt to contact the participant’s clinician with an in-built call button. Mode of delivery: mobile app and telephone. Individual basis. Health care provider: oncologists and researchers. | Frequency: study participants were 70% adherent to smartphone surveys. A total of 7 participants answered daily surveys ≥24 times a week. Actual patient engagement: 70%. |
Engagement outcomes (frequency, amount, duration, depth, and actual patient engagement)

Intervention description (content, mode of delivery, health care provider)

Yount et al [68]  
- Weekly calls to report symptoms, alerts triggered calls from a nurse (12 weeks)
  - Content: participants completed a symptom survey over the phone using the telephone keypad. Clinically significant symptoms were automatically reported to the clinical team for assessment and management with a nurse phone call. Data were also provided to physicians every 3 weeks before visits to facilitate discussion.
  - Mode of delivery: telephone. Individual basis.
  - Health care provider: physicians.

- Frequency: compliance with completion of weekly symptom monitoring phone calls was 82.1%.
- Actual patient engagement: 80.8%.

Across 44% (17/39) of studies, it was possible to create a standardized percentage of actual patient engagement compared with intended engagement [29,30,32,33,38-40,42,45,46,51,53,54,56,63,66-68]. This ranged from 51% [53] to 100% [29,30,64], with an average across all 17 studies of 75.4% (SD 15.8%). In the remaining 49% (19/39) of studies, it was not possible to create this standardized statistic because of a lack of reported data, and the design of the intervention meant there was no intended engagement and it was instead tailored to the patients’ needs.

Amount

A total of 31% (12/39) of studies measured the amount of contact with each intervention or with the intervention overall [32,35,36,38,39,43,44,46,47,50,53,57,58]. Of the 39 studies, 3 (8%) measured the average amount of time of each intervention.
contact (10.5 to 85 minutes) [35,47,57]. 2 (5%) reported the average amount of time across all intervention contacts (16 to 65 minutes) [38,39,46] and 1 (3%) reported the total amount of call durations, which could be averaged across all intervention participants to 35.3 minutes [44]. In total, 5% (2/39) of studies reported the median amount of time for each intervention contact (10 to 20 minutes) [32,58], and 5% (2/39) of studies reported the median amount of time across the whole intervention (38 to 146 minutes) [50,53]. A total of 3% (1/39) of studies reported the number of intervention contacts that fell into a range of minutes (eg, 16-30 minutes: 58 contacts) [36]. A total of 3% (1/39) of studies did not report time but, as it was a web-based intervention with communication with the health professional through posts on a message board, instead reported the average length of each post at 260.5 words [43].

**Duration**

A total of 15% (6/39) of studies that had open-ended interventions reported the length of time that each participant was exposed to the intervention [43,52,56-59]. A total of 10% (4/39) of studies reported the average time of exposure to the intervention, ranging from 62 to 195 days [43,52,57,59]. A total of 3% (1/39) of studies reported a median amount of exposure to the intervention of 6 months [58], and the final study (1/39, 3%) reported the number of participants exposed for >4 weeks (n=5) and >12 weeks (n=1) [56].

**Depth**

A total of 10% (4/39) of studies reported on the variety of components of the intervention that the participants accessed [36,43,50,64]. Each study measured depth in different ways. A total of 3% (1/39) of studies reported the percentage of time that each health professional was on the teleconference calls [64], and another study (1/39, 3%) simply reported that 75% of patients had completed all elements [43]. The number of different interventions that all participants received was reported by 3% (1/39) of studies [36], and the final study (1/39, 3%) reported that patients had viewed a median of 243 webpages [50].

**Association With Intervention Level of Intensity**

Expected levels of engagement for both patients and health professionals were reported across low (≤3 contacts), medium (4-7 contacts), and high (≥8 contacts) categories. A total of 13% (5/39) of studies could not be categorized as there was no expected engagement with the intervention, and the extent of engagement was determined at the patient’s discretion [32,36,43,55,63]. Table 3 shows the number of studies with the expected interaction of both the patient and health professional with the intervention. Most studies expected a similar level of interaction from both the patient and health professional in an intervention, but no studies expected more interaction from the health professional than from the patient.

**Table 3.** Number of studies with the expected engagement of the patient and health professional (n=34).

| Expected patient interaction with the intervention | Expected health professional interaction with the intervention |
|---------------------------------------------------|----------------------------------------------------------|
| Low                                               | Medium, n (%)    | High, n (%)    |
| Low                                               | 10 (26)         | —^a            |
| Medium                                            | 2 (5)           | 8 (21)         |
| High                                              | 7 (18)          | 7 (18)         |

^aNo data available for category.

Figures 2 and 3 are graphical representations of the association between expected levels of engagement for the patient (Figure 2) and the health professional (Figure 3) and the percentage of actual engagement with the intervention by the patient. Figure 2 shows that the studies that had low expected engagement for the patients had a combined actual patient engagement of 64% (SD 14.8%); for medium expected engagement, this was 66.9% (SD 16.4%); and, for high expected engagement, this was 87% (SD 8.2%). Figure 3 shows that the category with the highest level of combined actual patient engagement was the studies that expected the health professionals to have a high level of engagement with the intervention (86.6%, SD 8.3%). The studies in the categories of low and medium expected engagement from health professionals had lower levels of combined actual patient engagement (71%, SD 15.2% and 62.3%, SD 15%, respectively).
Figure 2. Box plot to present the association between expected levels of engagement by the patient and the percentage of actual engagement by the patient.

Figure 3. Box plot to present the association between expected levels of engagement by the health professional and the percentage of actual engagement by the patient.
Association With Intervention Mode of Delivery and Health Care Providers

Figure 4 [29-68] shows the modes of delivery of each intervention and where interventions use multiple modes, with the names in bold involving multiple health professionals. The figure also shows, where available, the percentage of actual patient engagement by way of color, with blue showing 90% to 100%, purple showing 70% to 89%, and red showing <70%. Of the 39 studies, 17 (44%) used multiple modes of delivery, whereas the remaining 22 (56%) used 1 mode. The telephone was the most popular mode of delivery (28/39, 72%) followed by web-based delivery of the intervention (17/39, 44%). The use of only a tablet or smartphone app for the intervention appeared to be associated with the most actual patient engagement with an intervention, with 8% (3/39) of studies showing between 90% and 100% engagement [54,56,65]. The use of a telephone was more mixed, with actual patient engagement ranging from 54.5% [51] to 100% [29,30]. Figure 4 also shows broadly how many health care providers were involved in delivering the interventions, with those involving multiple health care providers shown in bold. Those interventions that involved multiple health care providers reported higher patient engagement than those with only 1 health care provider (79.5%, SD 18.5% vs 70.5%, SD 11.5%).

Study Quality

The included studies could be grouped into two broad categories to be assessed using the Mixed Methods Appraisal Tool: quantitative RCTs and quantitative nonrandomized trials. The RCTs were of a broadly high quality; however, a number of studies did not provide enough information to assess whether the randomization procedure was conducted adequately or whether the groups at baseline were comparable. There were also 15% (6/39) of studies that did not have complete outcome data at follow-up. Among the nonrandomized trials, study quality was again high, apart from the included studies that did not control for confounders in their analysis. This is likely because most of these studies were feasibility or pilot studies and were not powered to detect significance, which would have been inappropriate. A breakdown of how each study was rated can be found in Multimedia Appendix 2 [29-68].

Discussion

Principal Findings

This systematic review is the first to synthesize engagement data from telehealth interventions for people with advanced cancer. This review found that people with advanced cancer were able to successfully engage in telehealth interventions with variable types of telehealth modalities, including telephone, mobile phone–based apps, and web-based interventions, albeit largely in the context of research studies. This review found that the frequency of engagement with the intervention was the
most commonly reported measure of engagement, although there was heterogeneity in the method of reporting across the studies. Where standardized comparison was possible across the studies, actual engagement as a proportion of intended engagement was at an average of 75.4% (SD 15.8%). The level of engagement was found to vary based on the expected interaction of both the patient and health care professional and the mode of delivery. Actual patient engagement was higher in studies that expected higher levels of engagement from both the patient and health care professional but was noticeably lower in studies that expected only a low or medium level of engagement. Furthermore, the use of only a tablet or smartphone app for an intervention appeared to be associated with the highest levels of actual patient engagement with an intervention. This could in part be explained by the immediacy of access and reduced steps for accessing an intervention through a mobile phone app when compared with an intervention hosted on a website.

This review is in line with previous reviews that looked at engagement with interventions involving digital technology among people with chronic diseases, which found broadly that there are high levels of engagement with interventions [20]. However, this review provides an overview and critique of existing reporting of engagement for telehealth interventions in patients with advanced cancer and found wide disparities in metrics for engagement used and reported across the included studies. The frequency of interaction with an intervention was reported widely, but other measures of engagement, such as the amount of time spent engaging with the intervention, were not reported as well. Furthermore, the duration and depth of engagement with the intervention were reported by only one-quarter of all included studies (9/39, 23%). This may be due to the design of interventions with a set duration or only 1 component that patients could engage with, but this was not clear across studies. In addition, few studies reported the expected levels of engagement for an intervention, limiting the interpretability of any subsequent reporting of actual patient engagement. Refining and using measures to better understand factors driving digital engagement, including for telehealth, could inform the development of approaches from design through monitoring as part of routine care. For example, the application of engagement measures could serve as a progression criterion in feasibility studies of emerging telehealth approaches. Future research may need to define and develop meaningful and context- and condition-appropriate measures of digital engagement for palliative care to facilitate measurement of digital engagement. Although this review focused on the quantitative measures of behavioral engagement, the future development of a measure should attempt to incorporate components that provide a broader understanding of subjective experiences and aspects of engagement, potentially through qualitative approaches. There is also scope to develop and refine the dimensions comprising the digital engagement framework used to guide the synthesis of data in this study. For example, there is scope to incorporate a temporal element to consider the intensity of the intervention (e.g., whether the intervention is spread over a week or months) alongside refining the underpinning definitions of terminology used for each dimension as the framework continues to evolve.

Through this review, we can conclude that there is no standardized method to report engagement in telehealth interventions for people with advanced cancer. The frequency of interactions with the intervention was presented most commonly, although the way in which this was done varied greatly across the studies, and there is a limited ability to understand what this means in the context of the intervention and the proposed and expected engagement needed for clinical utility. For example, people with advanced cancer have fluctuating needs, and a higher level of engagement with an intervention may not relate to the success of the intervention itself but be reflective of worsening outcomes for the patient [69]. In addition, patients may have their symptom management needs met early on in the intervention and may not need further follow-up, which may not be indicative of poor engagement with the intervention per se. With regard to mobile health interventions, the Mobile Health Evaluation, Reporting and Assessment checklist has been developed to help standardize the methodology for reporting the content and context of an intervention to support reproducibility and comparison of interventions [70]. Future iterations of the tool could include, for example, reporting of the expected and actual patient engagement levels of intended users of telehealth interventions alongside frequency of use—the most widely reported measure in this review. These data could complement and contribute to emerging evidence regarding the feasibility and acceptability of telehealth approaches as part of care for people with advanced cancer.

Recent evidence suggests that digital health interventions could provide a degree of efficacy related to QOL and psychosocial well-being [16]. For this review, most included interventions focused on symptom management, with high levels of engagement that suggest potential for its use to support remote monitoring. This approach could facilitate reductions in the required number of in-person visits while enabling continued access to data to inform patient care. However, in order to ensure such an approach is sustainable, there is a need to consider the burden of data entry on patients and the need for review—and potentially response—by health professionals. For patients, emerging approaches provide options for enhancing the richness of data received through remote monitoring without increasing the data burden for patients. For example, wearable technologies can passively collect sensor data on heart rate and activity to inform automatic monitoring and feedback processes [71], augmenting existing approaches without increasing the need for manual data entry. For health professionals, this review found that studies with high levels of intended engagement for both the patient and health care professional were associated with higher levels of actual engagement on the part of the patient. High intended engagement from health care professionals may not be a sustainable approach for digital technology, particularly when considered alongside the additional invisible work that such digital health can create for health professionals (e.g., data must be interpreted, made sense of, located within existing knowledge and data sets, and negotiated) [72]. This is important to consider in light of projections of an increasing burden of serious health-related suffering and subsequent demands on palliative care services across geographical regions where demand is increasingly

https://cancer.jmir.org/2022/1/e33355
outstripping supply [73, 74]. Therefore, for telehealth approaches to be sustainable as part of care for people with advanced cancer, they should seek to balance demands on both the patient and the care team, seeking to achieve maximal information with minimal data burden.

Limitations

There were a number of limitations associated with this review. First, the focus of engagement in this review was on the behavioral aspects that were outlined by Perski et al [19] but not on the subjective measures of engagement, such as interest, attention, and enjoyment. Integrating these subjective measures into a future mixed methods review could allow us to evaluate the experience of interventions. In addition, because of the heterogeneity of the studies and reported approaches to measuring engagement, such as frequency, it is difficult to determine exactly which components of interventions contribute to higher engagement levels. We were only able to draw associations, and future research is needed to better explore causal factors. Furthermore, although this review looked at the extent of engagement, how it was measured across studies, and the association with the study characteristics, we did not assess whether engagement led to an improvement in patient-reported outcomes or experience. A future review should consider how engagement interacts with patient-reported outcomes. In addition, when determining the categories for low, medium, and high expected engagement, we did not take into account the time frame of the intervention; therefore, 2 studies could be grouped together with different levels of intervention intensity. Furthermore, most of the studies included in this review explored the intervention effect through mostly controlled studies, which could bias the recruitment toward those individuals who were motivated and more likely to be technologically literate. The levels of engagement identified in this review may not then translate into routine clinical care if these studies and their intervention effect have to date been confined to exploration in the context of RCTs and similar study approaches. This review also limited the included studies to those written in English; therefore, this review may not contain the entirety of related studies.

Conclusions

This review identified that, where reported, there is a high level of engagement with telehealth interventions among people with advanced cancer. We identified that actual patient engagement is associated with both the expected level of engagement of the patient and the health professional as well as the mode of delivery of the intervention. We highlighted the heterogeneity in the reporting of engagement results across the research and the need to improve such reporting guidelines. As treatment delivery becomes increasingly more dependent on remote or telehealth modalities, the inclusion of a measure of engagement in future telehealth evaluations is essential to enable the comparisons of interaction and use across intervention approaches and to provide further granularity in factors that determine optimal implementation of telehealth approaches. There is a need for consistent measurement and reporting of domains relating to digital engagement (eg, breadth, duration, and frequency) with the scope to amend or develop measures. This will increase the ease of reporting of engagement in future studies, inform which telehealth intervention components are linked to variations in engagement, facilitate evidence syntheses, and support the development of condition-specific benchmarks of digital engagement for people with advanced cancer.

Acknowledgments

This work was funded in part by Yorkshire Cancer Research (award reference EN/LR1/007) and Macmillan Cancer Research (award reference 6488078).

Conflicts of Interest

None declared.

Multimedia Appendix 1

Search strategy for Ovid MEDLINE.

[DOCX File, 18 KB-Multimedia Appendix 1]

Multimedia Appendix 2

Quality appraisal tables of quantitative randomized controlled trials and nonrandomized trials.

[DOCX File, 20 KB-Multimedia Appendix 2]

References

1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021 Aug 15;127(16):3029-3030 [FREE Full text] [doi: 10.1002/cncr.33587] [Medline: 34086348]

2. Waller A, Girgis A, Johnson C, Lecathelinais C, Sibbritt D, Forstner D, et al. Improving outcomes for people with progressive cancer: interrupted time series trial of a needs assessment intervention. J Pain Symptom Manag 2012 Mar;43(3):569-581 [FREE Full text] [doi: 10.1016/j.jpainsymman.2011.04.020] [Medline: 22209224]
3. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manag 2016 Jun;51(6):1070-1090 [FREE Full text] [doi: 10.1016/j.jpainsymman.2015.12.340] [Medline: 27112310]

4. Henson LA, Maddocks M, Evans C, Davidson M, Hicks S, Higginson IJ. Palliative care and the management of common distressing symptoms in advanced cancer: pain, breathlessness, nausea and vomiting, and fatigue. J Clin Oncol 2020 Mar 20;38(9):905-914. [doi: 10.1200/jco.19.00470]

5. Bausewein C, Booth S, Gyseel M, Kühlbach R, Haberland B, Higginson IJ. Understanding breathlessness: cross-sectional comparison of symptom burden and palliative care needs in chronic obstructive pulmonary disease and cancer. J Palliat Med 2010 Sep;13(9):1109-1118. [doi: 10.1089/jpm.2010.0068] [Medline: 20836635]

6. Tang S, Liu L, Lin KC, Chung JH, Hsieh CH, Chou WC, et al. Trajectories of the multidimensional dying experience for terminally ill cancer patients. J Pain Symptom Manag 2014 Nov;48(5):863-874 [FREE Full text] [doi: 10.1016/j.jpainsymman.2014.01.011] [Medline: 24742788]

7. Patel MI, Periyakoil VS, Blayney DW, Moore D, Nevedal A, Asch S, et al. Redesigning cancer care delivery: views from patients and caregivers. J Oncol Pract 2017 Apr;13(4):291-302. [doi: 10.1200/jop.2016.017327]

8. Hanlon P, Daines L, Campbell C, McKinstry B, Weller D, Pinnock H. Telehealth interventions to support self-management of long-term conditions: a systematic metareview of diabetes, heart failure, asthma, chronic obstructive pulmonary disease, and cancer. J Med Internet Res 2017 May 17;19(5):e172 [FREE Full text] [doi: 10.2196/jmir.6688] [Medline: 28526671]

9. Aapro M, Bossi P, Darsari A, Fallowfield L, Gascón P, Geller M, et al. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer 2020 Oct;28(10):4589-4612 [FREE Full text] [doi: 10.1007/s00520-020-03939-1] [Medline: 32533435]

10. Burbury K, Wong Z, Yip D, Thomas H, Brooks P, Gilham L, et al. Telehealth in cancer care: during and beyond the COVID-19 pandemic. Intern Med J 2021 Jan;51(1):125-133 [FREE Full text] [doi: 10.1111/imj.15039] [Medline: 33572014]

11. Charalambous A. Utilizing the advances in digital health solutions to manage care in cancer patients. Asia Pac J Oncol Nurs 2019;6(3):234-237 [FREE Full text] [doi: 10.4103/apjon.apjon_72_18] [Medline: 31259218]

12. Warrington L, Absolom K, Conner M, Kellar I, Clayton B, Ayres M, et al. Electronic systems for patients to report and manage side effects of cancer treatment: systematic review. J Med Internet Res 2019 Jan 24;21(1):e10875 [FREE Full text] [doi: 10.2196/jmir.10875] [Medline: 30679145]

13. Lockie SJ, Bottorff JL, Robinson CA, Pesut B. Experiences of rural family caregivers who assist with commuting for palliative care. Can J Nurs Res 2010 Mar;42(1):74-91. [Medline: 20420092]

14. Pesut B, Robinson CA, Bottorff JL, Fyles G, Broughton S. On the road again: patient perspectives on commuting for palliative care. Pall Supp Care 2010 Mar 23;8(2):187-195. [Medline: 204742788]

15. Larson JL, Rosen AB, Wilson FA. The effect of telehealth interventions on quality of life of cancer patients: a systematic review and meta-analysis. Telemed J Health Clin 2018 Jun;24(6):397-405. [doi: 10.1089/tmj.2017.0112] [Medline: 29112484]

16. Kane K, Kennedy F, Absolom KL, Harley C, Velikova G. Palliative care interventions: systematic review and narrative synthesis. BMJ Support Palliat Care 2020 Apr 26. [doi: 10.1136/bmjspcare-2020-002820] [Medline: 33903259]

17. Mathews SC, McShea MJ, Hanley CL, Ravitz A, Labrique AB, Cohen AB. Digital health: a path to validation. NPJ Digit Med 2019 Oct;17;2(1):38 [FREE Full text] [doi: 10.1038/s41746-019-0111-3] [Medline: 31304384]

18. Dentzer S. Rx for the 'blockbuster drug' of patient engagement. Health Aff (Millwood) 2013 Feb;32(2):202 [FREE Full text] [doi: 10.1377/hlthaff.f.2013.0037] [Medline: 23381509]

19. Perski O, Blandford A, West R, Michie S. Conceptualising engagement with digital behaviour change interventions: a systematic review using principles from critical interpretive synthesis. Transl Behav Med 2017 Jun;7(2):254-267 [FREE Full text] [doi: 10.1007/s13142-016-0453-1] [Medline: 27966189]

20. Sawesi S, Rashrash M, Phalakorkule K, Carpenter JS, Jones JF. The impact of information technology on patient engagement and health behavior change: a systematic review of the literature. JMR Inf Serv 2016 Jun 21;4(1):e1 [FREE Full text] [doi: 10.2196/medinform.4514] [Medline: 26795082]

21. Lage D, El-Jawahri A, Fuh C, Newcomb R, Jackson V, Ryan D, et al. Functional impairment, symptom burden, and clinical outcomes among hospitalized patients with advanced cancer. J Natl Compr Canc Netw 2020 Jun;18(6):747-754. [doi: 10.6004/jnccn.2019.7385] [Medline: 32502982]

22. Bagnall AM, Ashley L, Hulme C, Jones R, Freeman C, Rithalia A, et al. Systematic review of effectiveness and cost-effectiveness of telehealth interventions for people with cancer that cannot be cured. PROSPERO. 2018. URL: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018117232 [accessed 2022-01-28]

23. Systematic reviews: CRD’s guidance for undertaking reviews in health care. In: Centre for Reviews and Dissemination. York: CRD, University of York; 2009.

24. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. Br Med J 2014 Mar 07;348(mar07 3):g1687 [FREE Full text] [doi: 10.1136/bmj.g1687] [Medline: 24609605]
25. Hong Q, Fábregues S, Bartlett F, Boardman F, Cargo M, Dagenais P, et al. The Mixed Methods Appraisal Tool (MMAT) version 2018 for information professionals and researchers. Edu Inform 2018 Dec 18;34(4):285-291 [FREE Full text] [doi: 10.3233/eti-180221]

26. Popay J, Roberts H, Bowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews. ESRC Methods Programme. 2006. URL: https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/fhm/dhr/chir/NSsynthesisguidanceVersion1-April2006.pdf [accessed 2022-01-28]

27. Malimvaaara A. Pure intervention effect or effect in routine health care - blinded or non-blinded randomized controlled trial. BMC Med Res Methodol 2018 Aug 31;18(1):91 [FREE Full text] [doi: 10.1186/s12874-018-0549-2] [Medline: 3070553]

28. Kerr DC, Ornelas IJ, Lilly MM, Calhoun R, Meischke H. Participant engagement in and perspectives on a web-based mindfulness intervention for 9-1-1 telecommunicators: multimethod study. J Med Internet Res 2019 Jun 19;21(6):e13449 [FREE Full text] [doi: 10.2196/13449] [Medline: 31219045]

29. Alter CL, Fleishman SB, Kornblith AB, Holland JC, Biano D, Levenson R, et al. Supportive telephone intervention for patients receiving chemotherapy: a pilot study. Psychosomatics 1996 Sep;37(5):425-431. [doi: 10.1016/s0033-3182(96)71529-3]

30. Badr H, Smith CB, Goldstein NE, Gomez JE, Redd WH. Dyadic psychosocial intervention for advanced lung cancer patients and their family caregivers: results of a randomized pilot trial. Cancer 2015 Jan 01;121(1):150-158 [FREE Full text] [doi: 10.1002/cncr.29009] [Medline: 25209975]

31. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes and their family caregivers: results of a randomized pilot trial. J Clin Oncol 2016 Feb 20;34(6):557-565. [doi: 10.1200/JCO.2015.63.0830] [Medline: 26645247]

32. Bensink M, Armfield N, Pinkerton R, Irving H, Hallahan A, Theodoros D, et al. Using videotelephony to support paediatric oncology-related palliative care in the home: from abandoned RCT to acceptability study. Palliat Med 2009 Apr 27;23(3):228-237. [doi: 10.1177/0269216308100251] [Medline: 19073783]

33. Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, et al. Mindfulness-based cognitive therapy in advanced prostate cancer: acceptability and efficacy by race. Transl Behav Med 2019 Jul 16;9(4):629-637 [FREE Full text] [doi: 10.1093/tbmcn/iby089] [Medline: 30285186]

34. Bruera E, Yennurajalingam S, Palmer JL, Perez-Cruz PE, Frisbee-Hume S, Allo JA, et al. Methylphenidate and/or a nursing skill intervention (lessons in linking affect and coping) for women with metastatic breast cancer. Psychooncology 2017 Dec 27;26(12):2101-2108 [FREE Full text] [doi: 10.1002/pon.4312] [Medline: 27862046]

35. Cleveland AK, Moynihan T, Basford JR, Nyman JA, Tuma ML, Macken DA, et al. The rationale, design, and methods of a randomized, controlled trial to evaluate the effectiveness of collaborative telecare in preserving function among patients with late stage cancer and hematologic conditions. Contemp Clin Trials 2018 Jan;64:254-264 [FREE Full text] [doi: 10.1016/j.cct.2017.08.021] [Medline: 28887068]

36. Cleveland AK, Moynihan T, Herrin J, Loprinzi C, Kroenke K. Effect of collaborative telehabilitation on functional impairment and pain among patients with advanced-stage cancer: a randomized clinical trial. JAMA Oncol 2019 May 01;5(5):644-652 [FREE Full text] [doi: 10.1001/jamaoncol.2019.0011] [Medline: 30946436]

37. Chow E, Wong R, Connolly R, Hruby G, Franzcr, Franssen E, et al. Prospective assessment of symptom palliation for patients attending a rapid response radiotherapy program. J Pain Symptom Manag 2001 Aug;22(2):649-656. [doi: 10.1016/s0885-3924(01)00313-x]

38. Clover JS, Schuyler D, Fuch BC, Brescia F, Arana GW. Remote psychotherapy for terminally ill cancer patients. J Telemed Telecare 2005 Jun 23;11(3):157-159. [doi: 10.1258/1357630503688741] [Medline: 15901444]

39. Dixon W, Pitsuskin E, Fairchild A, Ghosh S, Danielson B. The feasibility of telephone follow-up led by a radiation therapist: experience in a multidisciplinary bone metastases clinic. J Med Imaging Radiat Sci 2010 Dec;41(4):175-179 [FREE Full text] [doi: 10.1016/j.jmir.2010.10.003] [Medline: 31051877]

40. Donovan HS, Ward SE, Sereika SM, Knapp JE, Sherwood PR, Bender CM, et al. Web-based symptom management for women with recurrent ovarian cancer: a pilot randomized controlled trial of the WRITE Symptoms intervention. J Pain Symptom Manag 2014 Feb;47(2):218-230 [FREE Full text] [doi: 10.1016/j.jpainsymman.2013.04.005] [Medline: 24018206]

41. Eldeib HK, Abbassi MM, Hussein MM, Salem SE, Sabry NA. The effect of telephone-based follow-up on adherence, efficacy, and toxicity of oral capecitabine-based chemotherapy. Temel I J Health 2019 Jun;25(6):462-470. [doi: 10.1089/tnj.2018.0077] [Medline: 30048216]
45. Flannery M, Stein K, Dougherty D, Mohile S, Guido J, Wells N. Nurse-delivered symptom assessment for individuals with advanced lung cancer. Oncol Nurs Forum 2018 Sep 1;45(5):619-630. [doi: 10.1188/18.onf.619-630]

46. Fleisher L, Buzaglo J, Collins M, Millard J, Miller SM, Egleston BL, et al. Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. Patient Educ Couns 2008 Jun;71(3):378-387 [FREE Full text] [doi: 10.1016/j.pec.2008.02.017] [Medline: 18417312]

47. Fox J, Janda M, Bennett F, Langbecker D. An outreach telephone program for advanced melanoma supportive care: acceptability and feasibility. Eur J Oncol Nurs 2019 Oct;42:110-115. [doi: 10.1016/j.ejon.2019.08.010] [Medline: 31493669]

48. Fox RS, Moreno PI, Yanez B, Estabrook R, Thomas J, Bouchard LC, et al. Integrating PROMIS® computerized adaptive tests into a web-based intervention for prostate cancer. Health Psychol 2019 May;38(5):403-409 [FREE Full text] [doi: 10.1037/hea0000672] [Medline: 31045423]

49. Friis RB, Hjollund NH, Mejdahl CT, Pappot H, Skuladottir H. Electronic symptom monitoring in patients with metastatic lung cancer: a feasibility study. BMJ Open 2020 Jun 17;10(6):e035673 [FREE Full text] [doi: 10.1136/bmjopen-2019-035673] [Medline: 32554725]

50. Gustafson DH, DuBenske LL, Namkoong K, Hawkins R, Chih M, Atwood AK, et al. An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trial. Cancer 2013 May 1;119(9):1744-1751 [FREE Full text] [doi: 10.1002/cncr.27939] [Medline: 23355273]

51. Haddad P, Wilson P, Wong R, Williams D, Sharma N, Soban F, et al. The success of data collection in the palliative setting--telephone or clinic follow-up? Support Care Cancer 2003 Sep;11(9):555-559. [doi: 10.1007/s00520-003-0485-1] [Medline: 12811644]

52. Hennemann-Krause L, Lopes AJ, Araujo JA, Petersen EM, Nunes RA. The assessment of telemedicine to support outpatient palliative care in advanced cancer. Pall Supp Care 2014 Aug 27;13(4):1025-1030. [doi: 10.1017/s147895151400100x]

53. Keikes L, de Vos-Geelen J, de Groot JW, Punt CJ, Simkens LH, Trajkovic-Vidakovic M, et al. Implementation, participation and satisfaction rates of a web-based decision support tool for patients with metastatic colorectal cancer. Patient Educ Couns 2019 Jul;102(7):1331-1335. [doi: 10.1016/j.pec.2019.02.020] [Medline: 30852117]

54. Liu JF, Lee J, Strock E, Phillips R, Mari K, Killiam B, et al. Technology applications: use of digital health technology to enable drug development. JCO Clin Cancer Informat 2018 Dec;2(1):1-12. [doi: 10.1200/cci.17.00153]

55. Nemecek R, Huber P, Schur S, Masel EK, Baumann L, Hoeller C, et al. Telemedically augmented palliative care: empowerment for patients with advanced cancer and their family caregivers. Wien Klin Wochenschr 2019 Dec 30;131(23-24):620-626. [doi: 10.1017/s105955081910162-3] [Medline: 31667588]

56. Rasschaert M, Helsen S, Rolefo C, Van Brussel I, Ravelingien J, Peeters M. Feasibility of an interactive electronic self-report tool for oral cancer therapy in an outpatient setting. Support Care Cancer 2016 Aug 30;24(8):3567-3571. [doi: 10.1007/s00520-016-3186-2] [Medline: 27025594]

57. Rose J, Bowman K, Radziejwicz R, Lewis S, O'Toole E. Predictors of engagement in a coping and communication support intervention for older patients with advanced cancer. J Am Geriatr Soc 2009 Nov;57 Suppl 2:296-299. [doi: 10.1111/j.1532-5415.2009.02517.x] [Medline: 20122033]

58. Sardell S, Sharpe G, Ashley S, Guerrero D, Brada M. Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol (R Coll Radiol) 2000 Feb;12(1):36-41. [doi: 10.1053/coll.2000.9108] [Medline: 18417312]

59. Schmitz KH, Zhang X, Winkels R, Schleicher E, Mathis K, Doerksen S, et al. Developing "Nurse AMIE": a tablet-based supportive care intervention for women with metastatic breast cancer. Psychooncology 2020 Jan 06;29(1):232-236. [doi: 10.1002/pon.5301] [Medline: 31493669]

60. Schmitz KH, Zhang X, Winkels R, Schleicher E, Mathis K, Doerksen S, et al. Developing "Nurse AMIE": a tablet-based supportive care intervention for women with metastatic breast cancer. Psychooncology 2020 Jan 06;29(1):232-236. [doi: 10.1002/pon.5301] [Medline: 31493669]

61. Sherry V, Guerra C, Ranganathan A, Schneider S. Metastatic lung cancer and distress: use of the distress thermometer for patient assessment. Clin J Oncol Nurs 2017 Jun 1;21(3):379-383. [doi: 10.1188/17.cjv.379-383]

62. Trojan A, Huber U, Brauchbar M, Petrausch U. Consilium smartphone app for real-world electronically captured patient-reported outcome monitoring in cancer patients undergoing anti-PD-L1-directed treatment. Case Rep Oncol 2020;13(2):491-496 [FREE Full text] [doi: 10.1159/000507345] [Medline: 32518544]

63. Upton J. Nurse-led telephone assessments for patients receiving ipilimumab. Cancer Nurs Pract 2016 Mar 10;15(2):30-35. [doi: 10.7748/cnp.15.2.30.s21]

64. Voruganti T, Grunfeld E, Jamieson T, Kurhashi AM, Lokuge B, Krzyzanowska MK, et al. My team of care study: a pilot randomized controlled trial of a web-based communication tool for collaborative care in patients with advanced cancer. J Med Internet Res 2017 Jul 18;19(7):e219 [FREE Full text] [doi: 10.2196/jmir.7421] [Medline: 28720558]

65. Watanabe SM, Fairchild A, Pituskin E, Borgersen P, Hanson J, Fassbender K. Improving access to specialist multidisciplinary palliative care consultation for rural cancer patients by videoconferencing: report of a pilot project. Support Care Cancer 2013 Apr;21(4):1201-1207. [doi: 10.1007/s00520-012-1649-7] [Medline: 23161339]

66. Weaver A, Love SB, Larsen M, Shanyinde M, Waters R, Granger L, et al. A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes. Support Care Cancer 2014 Oct;22(10):2677-2685. [doi: 10.1007/s00520-014-2224-1] [Medline: 24771299]
66. Wright AA, Raman N, Staples P, Schonholz S, Cronin A, Carlson K, et al. The hope pilot study: harnessing patient-reported outcomes and biometric data to enhance cancer care. JCO Clin Cancer Inform 2018 Dec;2:1-12 [FREE Full text] [doi: 10.1200/CCI.17.00149] [Medline: 30652585]

67. Yanez B, McGinty HL, Mohr DC, Begale MJ, Dahn JR, Flury SC, et al. Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer. Cancer 2015 Dec 15;121(24):4407-4415 [FREE Full text] [doi: 10.1002/cncr.29658] [Medline: 26348661]

68. Yount SE, Rothrock N, Bass M, Beaumont JL, Pach D, Lad T, et al. A randomized trial of weekly symptom telemonitoring in advanced lung cancer. J Pain Symptom Manag 2014 Jun;47(6):973-989 [FREE Full text] [doi: 10.1016/j.jpainsymman.2013.07.013] [Medline: 24210705]

69. O'Brien H, Morton E, Kampen A, Barnes S, Michalak E. Beyond clicks and downloads: a call for a more comprehensive approach to measuring mobile-health app engagement. BJPsych Open 2020 Aug 11;6(5):e86 [FREE Full text] [doi: 10.1192/bjo.2020.72] [Medline: 32778200]

70. Agarwal S, LeFevre AE, Lee J, L'Engle K, Meh G, Sinha C, WHO mHealth Technical Evidence Review Group. Guidelines for reporting of health interventions using mobile phones: mobile health (mHealth) evidence reporting and assessment (mERA) checklist. Br Med J 2016 Mar 17;352:i1174 [FREE Full text] [doi: 10.1136/bmj.i1174] [Medline: 26988021]

71. Nwosu AC, Quinn C, Samuels J, Mason S, Payne TR. Wearable smartwatch technology to monitor symptoms in advanced illness. BMJ Support Palliat Care 2018 Jun 03;8(2):237 [FREE Full text] [doi: 10.1136/bmjspcare-2017-001445] [Medline: 29101119]

72. Lupton D. The digitally engaged patient: self-monitoring and self-care in the digital health era. Soc Theory Health 2013 Jun 19;11(3):256-270. [doi: 10.1057/sth.2013.10]

73. Lupu D, Quigley L, Mehfoud N, Salsberg ES. The growing demand for hospice and palliative medicine physicians: will the supply keep up? J Pain Symptom Manag 2018 Apr;55(4):1216-1223 [FREE Full text] [doi: 10.1016/j.jpainsymman.2018.01.011] [Medline: 29410071]

74. Sleeman KE, de Brito M, Etikind S, Nkhoma K, Guo P, Higginson IJ, et al. The escalating global burden of serious health-related suffering: projections to 2060 by world regions, age groups, and health conditions. Lancet Global Health 2019 Jul;7(7):883-892. [doi: 10.1016/s2214-109x(19)30172-x]

Abbreviations
- PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- PROSPERO: International Prospective Register of Systematic Reviews
- QOL: quality of life
- RCT: randomized controlled trial